Lantheus Holdings, Inc. (NASDAQ:LNTH) has been given an average rating of “Buy” by the six research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $18.60.

A number of research analysts have recently issued reports on the stock. BidaskClub cut shares of Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a report on Thursday. Zacks Investment Research upgraded shares of Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective for the company in a report on Thursday, August 3rd. Credit Suisse Group lifted their price objective on shares of Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and set a $22.00 price objective (up from $18.00) on shares of Lantheus Holdings in a report on Wednesday, August 2nd. Finally, Cantor Fitzgerald assumed coverage on shares of Lantheus Holdings in a report on Monday, July 17th. They set an “overweight” rating and a $22.00 price objective for the company.

Lantheus Holdings (NASDAQ LNTH) opened at 15.70 on Thursday. The company has a 50-day moving average of $18.08 and a 200-day moving average of $14.43. The firm has a market capitalization of $586.40 million, a price-to-earnings ratio of 21.45 and a beta of 0.91. Lantheus Holdings has a 52 week low of $5.68 and a 52 week high of $20.45.

Lantheus Holdings (NASDAQ:LNTH) last issued its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.18. The firm had revenue of $88.83 million during the quarter, compared to analysts’ expectations of $80.56 million. Lantheus Holdings had a net margin of 8.44% and a negative return on equity of 37.47%. The business’s revenue was up 13.9% on a year-over-year basis. During the same period last year, the company earned $0.24 earnings per share. On average, equities analysts forecast that Lantheus Holdings will post $1.12 earnings per share for the current fiscal year.

WARNING: “Lantheus Holdings, Inc. (LNTH) Given Consensus Recommendation of “Buy” by Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/17/lantheus-holdings-inc-lnth-given-consensus-recommendation-of-buy-by-brokerages.html.

In other news, insider Michael P. Duffy sold 20,000 shares of Lantheus Holdings stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $15.42, for a total transaction of $308,400.00. Following the completion of the transaction, the insider now directly owns 188,234 shares in the company, valued at $2,902,568.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mary Anne Heino sold 10,000 shares of Lantheus Holdings stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $15.39, for a total transaction of $153,900.00. Following the transaction, the chief executive officer now owns 602,468 shares of the company’s stock, valued at $9,271,982.52. The disclosure for this sale can be found here. Insiders have sold 3,321,692 shares of company stock valued at $50,117,821 over the last quarter. Corporate insiders own 2.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Lantheus Holdings by 87.5% in the second quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock valued at $26,093,000 after buying an additional 689,954 shares during the period. Marshall Wace North America L.P. boosted its position in Lantheus Holdings by 1,214.5% in the second quarter. Marshall Wace North America L.P. now owns 1,054,170 shares of the medical equipment provider’s stock valued at $18,975,000 after buying an additional 973,977 shares during the period. Renaissance Technologies LLC boosted its position in Lantheus Holdings by 12.6% in the second quarter. Renaissance Technologies LLC now owns 691,000 shares of the medical equipment provider’s stock valued at $12,196,000 after buying an additional 77,200 shares during the period. State Street Corp boosted its position in Lantheus Holdings by 3,932.8% in the second quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock valued at $10,891,000 after buying an additional 601,714 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Lantheus Holdings by 79.8% in the second quarter. Dimensional Fund Advisors LP now owns 524,540 shares of the medical equipment provider’s stock valued at $9,258,000 after buying an additional 232,856 shares during the period. Institutional investors and hedge funds own 71.53% of the company’s stock.

About Lantheus Holdings

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.